Clinical Efficacy Of Escitalopram Combined With RTMs In The Treatment Of Depressive Comorbiditis Type 2 Diabetes

Objective To investigate the clinical efficacy of Escitalopram oxalate combined with Repetitive transcranial magnetic stimulation(r TMS)in the treatment of depression with comorbidious type 2 diabetes.To compare the efficacy of escitalopram oxalate combined with r TMS and escitalopram oxalate alone in the treatment of depression with comorbid type 2diabetes,in order to seek a more scientific plan for clinical treatment.Methods Using simple random sampling method,the selection in December 2020-December 2021 in Inner Mongolia autonomous region at the records of comorbid mental health center hospital of type 2 diabetes patients with depression,will conform to the inclusion criteria and exclusion criteria,56 patients as the research object of this study,according to the indicator method is divided into two groups at random,28 cases were 28 cases in the control group and experimental group respectively.Control group was treated with escitalopram oxalate,initially 5mg/d,and the dose was gradually increased to 10-20mg/d according to the clinical manifestations of patients,and continued for 8 weeks.The experimental group was treated with escitalopram oxalate and repeated TRANSCranial magnetic stimulation for 8 weeks.Hamilton Depression Scale(HAMD)and Self-rating Depression Scale(SDS)were assessed before treatment and at the 2nd,4th and 8th weeks after treatment.At the same time,the incidence of adverse reactions in 2 groups was recorded.The chi-square test was used for comparison of counting data,the independent sample T test was used for comparison of measurement data between groups,and the two-factor repeated measure an OVA was used for comparison of two treatments of the same index at different time points,α=0.05.Results 1.There was no statistical significance in gender,marital status,age,years of education,course of diabetes,use of hypoglycemic drugs and maximum dose of escitalopram oxalate between the two groups(P > 0.05);2.There was no significant difference in HAMD scores between the two groups before and the second week after treatment(P > 0.05),but significant difference was found in the fourth and eighth week after treatment(P < 0.05);Before treatment,there was no significant difference in HAMD anxiety/somatization factor,block factor,sleep disorder factor,sense of despair factor and cognitive disorder factor between 2 groups(P > 0.05).After 8 weeks of treatment,anxiety/somatization factor,block factor,sleep disorder factor and sense of despair factor in the experimental group were significantly lower than those in the control group,the difference was statistically significant(P < 0.05).The effective rate of experimental group was significantly higher than that of control group(P < 0.05).3.Comparison of SDS scores between the two groups showed that there was no significant difference between the two groups before and the second week after treatment(P > 0.05),but the difference was statistically significant in the fourth and eighth week after treatment(P < 0.05);4.With the passage of time,HAMD and SDS scores showed significant differences at different time points after treatment(P < 0.05).Conclusions 1.Escitalopram oxalate combined with repeated transcranial magnetic stimulation in the treatment of depressive comorbiditis type 2 diabetes has significantly improved the depressive mood,and the effect is more obvious than that of single drug therapy,which is worthy of clinical promotion.2.The clinical efficacy of escitalopram oxalate combined with repeated transcranial magnetic stimulation in the treatment of depressive comorbiditis type 2 diabetes became more obvious with the extension of treatment cycle.